natgillin/translations-raw huggingface dataset:
Metformin Hydrochloride 850mgg 
Metformiinvesinikkloriid 850mgg
Latvia Ratiopharm Gmbh 
Ratiopharm Gmbh
Rosemont Pharmaceuticals Limited Metformin Hydrochloride Rosemont Pharmaceuticals 
Metformin Hydrochloride Rosemont Pharmaceuticals
Metformin Hydrochloride 1000mg Tablet, Empagliflozin 12.5mg Tablet 
Metformiinvesinikkloriid 1000mg Tablett, Empagliflosiin 12.5mg Tablett
Metformin Hydrochloride 1000mg Tablet, Linagliptin 2.5mg Tablet 
Metformiinvesinikkloriid 1000mg Tablett, Linagliptiin 2.5mg Tablett
Metformin Hydrochloride 100mg/ Ml 
Metformiinvesinikkloriid 100mg/ Ml
Metformin Hydrochloride 100mg/Ml 
Metformiinvesinikkloriid 100mg/Ml
Metformin/Glibenklamid Lek Metformin Hydrochloride 500mg Tablet, Glibenclamide 5mg Tablet 
Metformin/Glibenklamid Lek Metformiinvesinikkloriid 500mg Tablett, Glibenclamide 5mg Tablett
Metformin Hydrochloride 850mg Tablet, Alogliptin 25mg Tablet 
Metformiinvesinikkloriid 850mg Tablett, Alogliptiin 25mg Tablett
Metformin Hydrochloride 500mg/5 Ml 
Metformiinvesinikkloriid 500mg/5 Ml
Metformin Wockhardt Uk Ltd Metformin Hydrochloride 500mg Tablet 
Metformin Wockhardt Uk Ltd Metformiinvesinikkloriid 500mg Tablett Kaetud tablett
Metformin Hydrochloride 850mg Tablet, Linagliptin 2.5mg Tablet 
Metformiinvesinikkloriid 850mg Tablett, Linagliptiin 2.5mg Tablett
Austria 1a Pharma Gmbh 
1a Pharma Gmbh
Metformin/Glibenklamid Lek Metformin Hydrochloride 500mg Tablet, Glibenclamide 2.5mg Tablet 
Metformin/Glibenklamid Lek Metformiinvesinikkloriid 500mg Tablett, Glibenclamide 2.5mg Tablett
Metformin Hydrochloride 850mg Tablet, Dapagliflozin 5mg Tablet 
Metformiinvesinikkloriid 850mg Tablett, Dapagliflosizin 5mg Tablett
Metformine Hcl Usv Europe Metformin Hydrochloride 500mg Tablet 
Metformine Hcl Usv Europe Metformiinvesinikkloriid 500mg Tablett Õhukese polümeerikattega tablett
Metformin Hydrochloride 850mg 
Metformiinvesinikkloriid 850mg
Metformin Hydrochloride 500mg Units 
Metformiinvesinikkloriid 500mg Üksused
Metformin Hydrochloride 500mgg 
Metformiinvesinikkloriid 500mgg
Metformin Hydrochloride 850mg Tablet, Alogliptin 12.5mg Tablet 
Metformiinvesinikkloriid 850mg Tablett, Alogliptiin 12.5mg Tablett
Metformin Hydrochloride 850mg Tablet, Empagliflozin 12.5mg Tablet 
Metformiinvesinikkloriid 850mg Tablett, Empagliflosiin 12.5mg Tablett
Metformin Hydrochloride 850mg Tablet, Pioglitazone 15mg Tablet 
Metformiinvesinikkloriid 850mg Tablett, Pioglitasoon 15mg Tablett
Metformina Mylan Generics Metformin Hydrochloride 1000mg Tablet Film-Coated Tablet 
Metformina Mylan Generics Metformiinvesinikkloriid 1000mg Tablett Õhukese polümeerikattega tablett
Romania Aurobindo Pharma Limited 
Ühendkuningriik Aurobindo Pharma Limited
Metformina Mylan Generics Metformin Hydrochloride 500mg Tablet 
Metformina Mylan Generics Metformiinvesinikkloriid 500mg Tablett Õhukese polümeerikattega tablett
Metformin Hydrochloride 1000mg Tablet, Sitagliptin 50mg Tablet 
Metformiinvesinikkloriid 1000mg Tablett, Sitagliptiin 50mg Tablett
Metformin Hydrochloride 1000mg Tablet, Dapagliflozin 5mg Tablet 
Metformiinvesinikkloriid 1000mg Tablett, Dapagliflosiin 5mg Tablett
Germany Juta Pharma Gmbh 
Juta Pharma Gmbh
Metformin Hydrochloride 1000mg Tablet, Glibenclamide 5mg Tablet 
Metformiinvesinikkloriid 1000mg Tablett, Glibenclamide 5mg Tablett
Germany Tad Pharma Gmbh 
Tad Pharma Gmbh
Metformin Hydrochloride 1000mg Tablet Dispersible Tablet 
Metformiinvesinikkloriid 1000mg Tablett Dispergeeritav tablett
Metformin Crescent Pharma Metformin Hydrochloride 500mg Tablet 
Metformin Medley Pharma Metformiinvesinikkloriid 500mg Tablett Tablett
Metformin Hydrochloride 1000mg Tablet, Empagliflozin 5mg Tablet 
Metformiinvesinikkloriid 1000mg Tablett, Empagliflosiin 5mg Tablett
Metformin Hydrochloride 1000mg Tablet Prolonged-Release Tablet 
Metformiinvesinikkloriid 1000mg Tablett Toimeainet prolongeeritult vabastav tablett
Metformin Crescent Pharma Metformin Hydrochloride 850mg Tablet 
Metformin Medley Pharma Metformiinvesinikkloriid 850mg Tablett Tablett
Metformin Hydrochloride 1000mg Tablet, Canagliflozin 150mg Tablet 
Metformiinvesinikkloriid 1000mg Tablett, Kanagliflosiin 150mg Tablett
Metformin Hydrochloride 1000mg Tablet, Canagliflozin 50mg Tablet 
Metformiinvesinikkloriid 1000mg Tablett, Kanagliflosiin 50mg Tablett
Metformina Mylan Generics Metformin Hydrochloride 850mg Tablet 
Metformina Mylan Generics Metformiinvesinikkloriid 850mg Tablett Suus dispergeeruv ravimkile
Eood 
Leedu
Metformin Lindopharm Metformin Hydrochloride 500mg Tablet 
Metformin Lindopharm Metformiinvesinikkloriid 500mg Tablett Õhukese polümeerikattega tablett
Metformin Relonchem Metformin Hydrochloride 500mg Tablet 
Metformin Relonchem Metformiinvesinikkloriid 500mg Tablett Õhukese polümeerikattega tablett
Metformin Hydrochloride 400mg Tablet, Glibenclamide 2.5mg Tablet 
Metformiinvesinikkloriid 400mg Tablett, Glibenclamide 2.5mg Tablett
Metformin Hydrochloride 500mg G 
Metformiinvesinikkloriid 500mg
Metformin Hydrochloride 850mg Tablet, Empagliflozin 5mg Tablet 
Metformiinvesinikkloriid 850mg Tablett, Empagliflosiin 5mg Tablett
Metformin Hydrochloride 1000mg Tablet Tablet 
Metformiinvesinikkloriid 1000mg Tablett Kihisev tablett
Metformin Hydrochloride 500mg Tablet, Glibenclamide 2.5mg Tablet 
Metformiinvesinikkloriid 500mg Tablett, Glibenclamide 2.5mg Tablett
Metformin Hydrochloride 850mg Tablet, Sitagliptin 50mg Tablet 
Metformiinvesinikkloriid 850mg Tablett, Sitagliptiin 50mg Tablett
Metformin Hcl Ratiopharm Metformin Hydrochloride 850mg Tablet 
Metformin Hcl Ratiopharm Metformiinvesinikkloriid 850mg Tablett Õhukese polümeerikattega tablett
Metformin Hcl Ratiopharm Metformin Hydrochloride 500mg Tablet 
Metformin Hcl Ratiopharm Metformiinvesinikkloriid 500mg Tablett Õhukese polümeerikattega tablett
Metformin Hydrochloride 400mg Tablet, Glibenclamide 5mg Tablet 
Metformiinvesinikkloriid 400mg Tablett, Glibenclamide 5mg Tablett
Metformin Hydrochloride 2.5mg Tablet, Glibenclamide 500mg Tablet 
Metformiinvesinikkloriid 2.5mg Tablett, Glibenclamide 500mg Tablett
Metformin Hydrochloride 500mg Tablet, Glibenclamide 5mg Tablet 
Metformiinvesinikkloriid 500mg Tablett, Glibenclamide 5mg Tablett
Metformin Hcl Ratiopharm Metformin Hydrochloride 1000mg Tablet Film-Coated Tablet 
Metformin Hcl Ratiopharm Metformiinvesinikkloriid 1000mg Tablett Õhukese polümeerikattega tablett
Metformin Hydrochloride 850mg Tablet, Canagliflozin 150mg Tablet 
Metformiinvesinikkloriid 850mg Tablett, Kanagliflosiin 150mg Tablett
Metformin Lindopharm Metformin Hydrochloride 850mg Tablet 
Metformin Lindopharm Metformiinvesinikkloriid 850mg Tablett Õhukese polümeerikattega tablett
Metformin-Ratiopharm Metformin Hydrochloride 500mg Tablet 
Metformin-Ratiopharm Metformiinvesinikkloriid 500mg Tablett Õhukese polümeerikattega tablett
Metformin-Ratiopharm Metformin Hydrochloride 850mg Tablet 
Metformin-Ratiopharm Metformiinvesinikkloriid 850mg Tablett Õhukese polümeerikattega tablett
Metformin Hydrochloride 500mg Film Film-Coated Tablet 
Metformiinvesinikkloriid 500mg Tablett Kaetud tablett
Germany Denk Pharma Gmbh & Co. Kg Metfo 
Denk Pharma Gmbh & Co.
Metformin Hydrochloride 850mg Tablet, Canagliflozin 50mg Tablet 
Metformiinvesinikkloriid 850mg Tablett, Kanagliflosiin 50mg Tablett
Metformin Relonchem Metformin Hydrochloride 850mg Tablet 
Metformin Relonchem Metformiinvesinikkloriid 850mg Tablett Õhukese polümeerikattega tablett
Metformin Hydrochloride 1000mg Tablet, Saxagliptin 2.5mg Tablet 
Metformiinvesinikkloriid 1000mg Tablett, Saksagliptiin 2.5mg Tablett
Metformine Hcl Ratiopharm Metformin Hydrochloride 1000mg Tablet Film-Coated Tablet 
Metformine Hcl Ratiopharm Metformiinvesinikkloriid 1000mg Tablett Õhukese polümeerikattega tablett
Metformin Ratiopharm Metformin Hydrochloride 850mg Tablet 
Metformin Ratiopharm Metformiinvesinikkloriid 850mg Tablett Õhukese polümeerikattega tablett
Metformin Hcl Plus Pharmacie Metformin Hydrochloride 1000mg Tablet Film-Coated Tablet 
Metformine Mylan Pharma Metformiinvesinikkloriid 1000mg Tablett Õhukese polümeerikattega tablett
Metformin Ratiopharm Metformin Hydrochloride 500mg Tablet 
Metformin Ratiopharm Metformiinvesinikkloriid 500mg Tablett Õhukese polümeerikattega tablett
Metformine Hcl Ratiopharm Metformin Hydrochloride 500mg Tablet 
Metformine Hcl Ratiopharm Metformiinvesinikkloriid 500mg Tablett Õhukese polümeerikattega tablett
Metformin Glenmark 
Glenmark Arzneimittel Gmbh Metformin Glenmark
Metformin Ratiopharm Metformin Hydrochloride 1000mg Tablet Film-Coated Tablet 
Metformin Ratiopharm Metformiinvesinikkloriid 1000mg Tablett Õhukese polümeerikattega tablett
Metformina Ratiopharm Metformin Hydrochloride 1000mg Tablet Film-Coated Tablet 
Metformina Ratiopharm Metformiinvesinikkloriid 1000mg Tablett Õhukese polümeerikattega tablett
Metformina Ratiopharm Metformin Hydrochloride 500mg Tablet 
Metformina Ratiopharm Metformiinvesinikkloriid 500mg Tablett Õhukese polümeerikattega tablett
Metformina Ratiopharm Metformin Hydrochloride 850mg Tablet 
Metformina Ratiopharm Metformiinvesinikkloriid 850mg Tablett Õhukese polümeerikattega tablett
Metformin Hydrochloride 850mg Tablet, Saxagliptin 2.5mg Tablet 
Metformiinvesinikkloriid 850mg Tablett, Saksagliptiin 2.5mg Tablett
Some patients were treated for up to five and a half years. 
Osa patsiente raviti kuni viis ja pool aastat.
It is available as capsules (100 mg). 
Seda turustatakse kapslitena (100 mg).
• Gaucher disease; 
• Gaucher' tõbi;
Zavesca is intended for long-term use. 
Zavesca on ette nähtud pikaajaliseks kasutamiseks.
The main part of the study lasted for a year, but 13 patients carried on receiving the medicine for a further two years. 
Uuringu põhiosa kestis üks aasta, kuid 13 patsienti said ravimit veel kaks aastat.
The European Commission granted a marketing authorisation valid throughout the European Union for Zavesca on 20 November 2002. 
Euroopa Komisjon andis Zavesca müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 20. novembril
There were also small improvements in blood counts: on average, the levels of haemoglobin increased by 0.26 g per decilitre and platelet counts increased by 8.29 million per millilitre. 
Ka verenäitajad paranesid mõnevõrra: hemoglobiini sisaldus suurenes keskmiselt 0,26 g/dl võrra ja trombotsüütide sisaldus suurenes 8,29 miljoni võrra milliliitri kohta.
As the company had supplied the additional information requested, the exceptional circumstances ended on 23 August 2012. 
Et ettevõte esitas nõutud lisateabe, tühistati 23. augustil 2012 müügiloa erandkorras väljastatus.
EPAR summary for the public miglustat 
Kokkuvõte üldsusele miglustaat
The company also presented the results of a survey of 66 patients treated with Zavesca. 
Ettevõte esitas samuti Zavescaga ravitud 66 patsiendi uuringu tulemused.
Zavesca is used to treat the following patients: 
Zavescat kasutatakse järgmiste patsientide ravis:
The summaries of the opinions of the Committee for Orphan Medicinal Products for Zavesca on the Agency's website ema.europa.eu/Find medicine/Human medicines/Rare disease designations: 
Harvikravimite komitee arvamuste kokkuvõtted Zavesca kohta on ameti veebilehel aadressil ema.europa.eu/Find medicine/Human medicines/Rare disease designations:
The full EPAR for Zavesca can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Euroopa avaliku hindamisaruande täistekst Zavesca kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Zavesca was originally authorised under ‘exceptional circumstances' because, as the diseases are rare, limited information was available at the time of approval. 
Esialgu kiideti Zavesca heaks erandkorras, sest haigus esineb harva ja ravimi heakskiitmise ajal ei olnud piisavalt teavet.
The main measure of effectiveness was the change in the speed at which the patients made saccadic horizontal eye movements after a year, but the study also looked at other neurological symptoms such as the patients' ability to swallow and their intellectual function. 
Efektiivsuse põhinäitaja oli muutus patsiendi sakaadiliste horisontaalsete silmaliigutuste kiiruses pärast üheaastast ravi, kuid vaadeldi ka teisi neuroloogilisi sümptomeid, nagu patsiendi neelamisvõime ja vaimsed võimed.
What is the risk associated with Zavesca? 
Mis riskid Zavescaga kaasnevad?
The CHMP decided that Zavesca's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Inimravimite komitee otsustas, et Zavesca kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
For Niemann-Pick type C disease, it is two capsules three times a day for patients aged 12 years and over; in younger patients, the dose depends on their weight and height. 
C-tüüpi Niemanni-Picki tõve korral on vähemalt 12-aastaste patsientide algannus kaks kapslit kolm korda ööpäevas, nooremate patsientide annus oleneb nende kaalust ja pikkusest.
What is Zavesca? 
Mis on Zavesca?
Why has Zavesca been approved? 
Miks Zavesca heaks kiideti?
Because the number of patients with these diseases is low, they are considered ‘rare', and Zavesca was designated an ‘orphan medicine' (a medicine used in rare diseases) on 18 October 2000 for type 1 Gaucher disease and on 16 February 2006 for Niemann-Pick type C disease. 
Et nende haigustega patsiente on vähe ja neid haigusi esineb harva, nimetati Zavesca 18. oktoobril 2000 I tüüpi Gaucher' tõve ja 16. veebruaril 2006 C-tüüpi Niemanni-Picki tõve harvikravimiks.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zavesca. 
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
• Niemann-Pick type C disease. 
• C-tüüpi Niemanni-Picki tõbi.
These include loss of co-ordination, problems with ‘saccadic' (rapid) eye movements that can lead to impaired vision, delayed development, difficulty swallowing, decreased muscle tone, fits and learning difficulties. 
Nende hulka kuuluvad koordinatsioonivõime kadumine, sakaadiliste (aktiivse vaatlemisega seotud kiirete) silmaliigutuste häired, mis võivad halvendada nägemist, arengupeetus, neelamisraskused, lihastoonuse vähenemine, krambid ja õppimisraskused.
Zavesca is used to treat the neurological symptoms of the disease (symptoms affecting the brain and nerves). 
Zavescaga ravitakse haiguse neuroloogilisi (peaaju ja närve mõjutavaid) sümptomeid.
For the full list of all side effects reported with Zavesca, see the package leaflet. 
Zavesca kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
For more information about treatment with Zavesca, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Kui vajate Zavescaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
For Niemann-Pick type C disease, Zavesca was studied in one main study involving 31 patients, 12 of whom were less than 12 years old. 
Zavesca efektiivsust C-tüüpi Niemanni-Picki tõve korral uuriti ühes põhiuuringus, milles osales 31 patsienti, kellest 12 olid alla 12-aastased.
• adults (aged 18 years and above) with mild to moderate type 1 Gaucher disease. 
• vähemalt 18-aastased täiskasvanud kerge või mõõduka I tüüpi Gaucher' tõvega.
Zavesca is a medicine that contains the active substance miglustat. 
Zavesca on ravim, mis sisaldab toimeainena miglustaati.
Zavesca must not be used in people who are hypersensitive (allergic) to miglustat or any of the other ingredients. 
Zavescat ei tohi kasutada patsiendid, kes on miglustaadi või ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
This is expected to slow down or prevent the development of the symptoms of type 1 Gaucher disease and to reduce the symptoms of Niemann-Pick type C disease. 
Eeldatavasti aeglustab või ennetab miglustaat sel viisil I tüüpi Gaucher' tõve sümptomite teket ja vähendab C-tüüpi Niemanni-Picki tõve sümptomeid.
Zavesca is used in patients who cannot receive the standard treatment of enzyme replacement therapy (ERT); 
Zavescat kasutatakse patsientidel, keda ei saa ravida standardse ensüümiasendusraviga;
The study looked at the effect of Zavesca on the size of the liver and spleen, and at blood counts, such as the levels of haemoglobin (a protein found in red blood cells that carries oxygen around the body) and platelets (components that help the blood to clot). 
Uuringus jälgiti Zavesca toimet maksa ja põrna suurusele ning verenäitajatele, nagu hemoglobiini (vere punaliblede valk, mis kannab hapnikku organismis laiali) ja trombotsüütide (vereliistakud ehk hüübimist soodustavad vererakud) sisaldus.
The recommended starting dose for type 1 Gaucher disease is one capsule three times a day. 
Soovitatav algannus I tüüpi Gaucher' tõve korral on üks kapsel kolm korda ööpäevas.
In the study of Niemann-Pick type C disease, the improvement in eye movements was similar in patients treated with and without Zavesca. 
C-tüüpi Niemanni-Picki tõve uuringus oli silmaliigutuste paranemine Zavescaga ravitud patsientidel samalaadne kui neil, kes Zavesca ravi ei saanud.
Patients with this disease lack an enzyme called glucocerebrosidase, which results in a glycosphingolipid called glucosylceramide building up in different parts of the body, such as the spleen, liver and bones. 
Selle haigusega patsientidel on ensüümi glükotserebrosidaasi vaegus, mistõttu koguneb eri kehaosadesse, näiteks põrna, maksa ja luudesse, glükosüültseramiidiks nimetatavat glükosfingolipiidi.
The benefits of Zavesca were maintained over three years of continuous treatment. 
Zavesca kasulikkus säilis enam kui kolm aastat kestnud ravis.
The most common side effects with Zavesca (seen in more than 1 patient in 10) are weight loss, decreased appetite, tremor (shaking), diarrhoea, flatulence (gas) and abdominal pain (stomach ache). 
Zavesca kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on kehakaalu vähenemine, söögiisu vähenemine, värin, kõhulahtisus, kõhupuhitus ja kõhuvalu.
This document is a summary of the European Public Assessment Report (EPAR) for Zavesca. 
See on ravimi Zavesca Euroopa avaliku hindamisaruande kokkuvõte.
Both diseases cause a build-up of fatty substances called glycosphingolipids in the body. 
Mõlemad haigused põhjustavad rasvainete glükosfingolipiidide teket organismis.
The study compared the effects of adding Zavesca to standard care with the effects of standard care alone. 
Uuringus võrreldi Zavesca ja tavalise ravi koosmõju tavalise ravi mõjuga.
Zavesca is used to treat two inherited diseases that affect the way the body handles fats. 
Zavescaga ravitakse kaht harvaesinevat pärilikku haigust, mis mõjutavad rasvade ainevahetust organismis.
How is Zavesca used? 
Kuidas Zavescat kasutatakse?
A lower dose should be used in patients with reduced kidney function. 
Vähenenud neerutalitlusega patsientidel peab kasutama väiksemat annust.
For further information, see the summary of product characteristics (also part of the EPAR). 
Üksikasjalik teave on ravimi omaduste kokkuvõttes (samuti Euroopa avaliku hindamisaruande osa).
The survey showed that Zavesca led to a stabilisation or a decrease in the rate at which symptoms got worse in about three-quarters of the patients. 
Uuring näitas, et ligikaudu kolmel neljandikul patsientidest stabiliseeris Zavesca sümptomeid või vähendas nende progresseerumise kiirust.
What benefit has Zavesca shown during the studies? 
Milles seisneb uuringute põhjal Zavesca kasulikkus?
This enzyme is involved in the first step of the production of glycosphingolipids. 
See ensüüm osaleb glükosfingolipiidide tekke esimesel etapil.
In the study of type 1 Gaucher disease, there were moderate reductions in the size of the liver (12% reduction) and the spleen (19% reduction) after a year. 
I-tüüpi Gaucher' tõvega patsientide uuringus vähenes maksa ja põrna suurus ühe aasta möödudes veidi, vastavalt 12% ja 19%.
What is Zavesca used for? 
Milleks Zavescat kasutatakse?
By preventing the enzyme from working, miglustat can reduce the production of glycosphingolipids in cells. 
Ensüümi toime pärssimisega vähendab miglustaat glükosfingolipiidide teket rakkudes.
However, there were signs of improvement in swallowing ability and intellectual function in the patients treated with Zavesca. 
Zavesca ravi saanud patsientidel täheldati siiski neelamisvõime ja vaimsete võimete paranemist.
For type 1 Gaucher disease, Zavesca was investigated in one main study involving 28 adults with mild to moderate disease who were unable or unwilling to receive ERT. 
Zavesca efektiivsust I tüüpi kerge kuni mõõduka Gaucher' tõve ravis uuriti ühes põhiuuringus 28 patsiendil, kellele ensüümasendusravi ei saanud teha või kes seda ei soovinud.
The active substance in Zavesca, miglustat, prevents an enzyme called glucosylceramide synthase from working. 
Zavesca toimeaine miglustaat pärsib ensüümi glükosüültseramiidsüntaasi toimet.
Other information about Zavesca: 
Muu teave Zavesca kohta
The medicine can only be obtained with a prescription. 
Zavesca on retseptiravim.
Treatment with Zavesca should be started and monitored by doctors who are experienced in the management of Gaucher or Niemann-Pick type C disease. 
Ravi Zavescaga tohib alustada üksnes Gaucher' tõve või C-tüüpi Niemanni-Picki tõve ravis kogenud arst ning ravi peab toimuma tema järelevalve all.
The dose should also be reduced temporarily in patients who develop diarrhoea. 
Patsientidel, kellel tekib kõhulahtisus, peab annust ajutiselt vähendama.
• patients of all ages with Niemann-Pick type C disease, a potentially fatal disease in which glycosphingolipids build up within cells in the brain and elsewhere in the body. 
See võib olla surmav haigus, mille korral patsientidel ladestub ajurakkudesse ja mujale organismi glükosfingolipiide.
How does Zavesca work? 
Kuidas Zavesca toimib?
The European Commission issued a decision on 22 August 2016. 
Euroopa Komisjon tegi otsuse 22. augustil 2016.
The procedure was concluded and on 11 July 2014 the European Commission adopted a Decision1. 
Menetlus lõpetati ja 11. juulil 2014 tegi Euroopa Komisjon otsuse
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom22 August 2016 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom22.
Outcome of a referral procedure under Article 35 of Directive 2001/82/EC (EMEA/V/A/110) 
Direktiivi 2001/82/EÜ artikli 35 kohase esildismenetluse (EMEA/V/A/110) tulemused
The full changes made to the product information for powders for use in the drinking water are detailed in Annex III of the CVMP opinion on the 'All documents' tab. 
Täielik ülevaade joogiveega manustatavate pulbrite ravimiteabe muudatustest on veterinaarravimite komitee arvamuse III lisa jaotises „Kõik dokumendid“.
What are lincomycin and spectinomycin? 
Mis on linkomütsiin ja spektinomütsiin?
Commission Decision concerning, in the framework of Article 34 of Directive 2001/82/EC of the European Parliament and of the Council, the marketing authorisations for “Linco-Spectin 100 and its associated names”, veterinary medicinal products which contain the active substances “Lincomycin and spectinomycin” ((2014)5053 of 11/07/2014) http://ec.europa.eu/health/documents/community-register/html/vo25233.htm 
Komisjoni otsus, mis käsitleb Euroopa Parlamendi ja nõukogu direktiivi 2001/82/EÜ artikli 34 raames linkomütsiini ja spektinomütsiini sisaldava veterinaarravimi Linco-Spectin 100 ja sarnasete nimetuste müügilube ((2014)5053, 11.7.2014) http://ec.europa.eu/health/documents/community-register/html/vo25233.htm
Why were veterinary medicinal products containing a combination of lincomycin and spectinomycin reviewed? 
Miks vaadati linkomütsiini ja spektinomütsiini kombinatsiooni sisaldavate veterinaarravimite teave läbi?